Open access
Sep 2026
Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.
BACKGROUND Conventional response endpoints do not adequately capture durable clinical benefit in mycosis fungoides (MF) and Sézary syndrome (SS). Overall response lasting ≥ 4 months (ORR4) has been proposed as a clinically meaningful endpoint in clinical trials, but its prognostic value in real-world mogamulizumab-trea...
G. Roccuzzo, P. Fava, S. Rupoli et al.
· British Journal of Dermatolo... · 0 citations